Carl Chang, MD
Dermatology · Arcadia, CANPI 1891983078
Payments from drug & device makers
Across 93 payments — averaging $26.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$449
- Sanofi$374
- Pfizer$333
- AbbVie$264
- Johnson & Johnson$253
- UCB, Inc.$161
- plus $660 from 12 others
What the payments were for
- Food & beverage$2,16087%
- Education$33313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 17 | $449 |
| Sanofi | 9 | $374 |
| Pfizer | 21 | $333 |
| AbbVie | 14 | $264 |
| Johnson & Johnson | 5 | $253 |
| UCB, Inc. | 5 | $161 |
| Galderma Laboratories, L.p. | 5 | $128 |
| Regeneron Healthcare Solutions, Inc. | 3 | $106 |
| LEO Pharma Inc. | 3 | $98 |
| Novartis | 1 | $67 |
| Bristol Myers Squibb | 1 | $51 |
| Amgen | 2 | $44 |
| Sun Pharmaceutical Industries Inc. | 1 | $33 |
| Almirall LLC | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Dermavant Sciences, Inc. | 1 | $24 |
| Organon | 1 | $24 |
| Smith+Nephew | 1 | $21 |
How this compares
$2,493 in reported general payments places this provider in the 55th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pimecrolimus | 12 | $3,472 |
| Clobetasol Propionate | 44 | $2,761 |
| Ketoconazole | 136 | $1,998 |
| Fluorouracil | 29 | $1,838 |
| Triamcinolone Acetonide | 144 | $1,513 |
| Betamethasone Dipropionate | 22 | $1,192 |
| Tacrolimus | 12 | $1,179 |
| Metronidazole | 20 | $1,122 |
| Halobetasol Propionate | 19 | $1,093 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 15 | $870 |
| Fluocinonide | 16 | $577 |
| Fluocinolone Acetonide | 13 | $463 |
| Clotrimazole | 17 | $381 |
| Econazole Nitrate | 12 | $360 |
| Clindamycin Phosphate | 17 | $352 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Arcadia
- Vivian LaquerIrvine$20.9M
- Howard SofenLos Angeles$16.1M
- Raja SivamaniSacramento$11.8M
- Jennifer SoungSanta Ana$10.3M
- Stacy SmithEncinitas$7.9M
- Paul YamauchiSanta Monica$7.8M
- Navid EzraThousand Oaks$7.8M
- Paul WallaceBeverly Hills$7.1M
- April ArmstrongLos Angeles$6.2M
- David RayhanHuntington Beach$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.